BioCentury
ARTICLE | Clinical News

Topical dexchlorpheniramine antihistamine that uses lipid solubility to enhance skin penetration: Began Phase IB/II dose-escalation trial

February 6, 1995 8:00 AM UTC

Arcturus Pharmaceutical Corp., Woburn, Mass. Product: Topical dexchlorpheniramine antihistamine that uses lipid solubility to enhance skin penetration Indication: Treat pruritis (itch) in patients wit...